Itanapraced

Itanapraced is a first-in-class, orally active small molecule developed as a modulator of neuroinflammation and neurodegeneration. It acts primarily as an amyloid precursor protein intracellular domain (AICD) inhibitor, binding to AICD and inhibiting its transcriptional activity. This mechanism reduces the expression of pro-apoptotic and neurotoxic factors such as BIM, PINK1, LRRK2, and others that contribute to neuronal loss in conditions like Alzheimer's disease and Parkinson's disease. Itanapraced also functions as a gamma-secretase modulator that reduces secretion of amyloid-beta peptides (Aβ42 and Aβ40), which are implicated in Alzheimer's pathology. The drug has demonstrated the ability to reverse damage to dopamine-producing neurons in preclinical models of Parkinson's disease by disrupting the pathological loop between AICD and LRRK2[1][5][6][7]. Developed initially by Chiesi and later advanced by CereSpir, itanapraced has completed phase II clinical trials for mild cognitive impairment.

Other names

itanapracedum1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acidC35RF1MWQZC-35RF1MWQZC 35RF1MWQZ